Choroidal Neovascularization (CNV) Market - Forecast(2022 - 2027)

Report Code: HCR 0119 Report Format: PDF + Excel

Choroidal Neovascularization (CNV) Market Overview

Choroidal Neovascularization (CNV) Market Size was $5.1 billion in 2021. Furthermore, it is poised to grow at a CAGR of 6.8% over the forecast period of 2022-2027. The choroid is the portion of the eye between the retina (vision sensory area) and the sclera (outside covering of the eye), and it is made up of blood vessels that feed nutrients to the retina. Choroidal Neovascularization is a condition in which new blood vessels grow as a result of the presence of vascular endothelial growth factor (VGEF) or as a result of Age-related Macular Degeneration (AMD). Usually, AMD is owing to neovascular degenerative maculopathy. Moreover, Choroidal neovascularization is a common cause of neovascular degenerative maculopathy. Furthermore, CNV is commonly caused by extreme myopia, malignant myopic degeneration, or age-related developments. Diabetic retinopathy patients potentially have choroidal neovascularization (CNV). It can happen in people who have deficiencies in Bruch's membrane, the choroid's innermost layer, in rare situations. Patients with Choroidal Neovascularization in one eye have a very high likelihood of contracting Choroidal Neovascularization in the other eye within a short period of time, according to the American Academy of Ophthalmology and other research. The growing prevalence of sedentary lifestyle diseases especially diabetes which can lead to diabetic retinopathy and the rising aged population are some of the factors driving the Choroidal Neovascularization Industry growth during the forecast period 2022-2027.

Choroidal Neovascularization Market Report Coverage

The report: “Choroidal Neovascularization Market Forecast (2022-2027)", by Industry ARC covers an in-depth analysis of the following segments of the Choroidal Neovascularization Market.

By Type- Type-1 (occult), Type-2 (classic), and Type-3.
By Application- Age-related Macular Degeneration, Ocular Histoplasmosis, Pathologic Myopia, Eye trauma, and Angioid Streaks.
By Treatment-Anti VEGF drugs, Thermal Laser Treatment (TLT), and Others.
By Geography- North America (U.S., Canada, Mexico), Europe (Germany, United Kingdom (U.K.), France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, Japan India, South Korea, Australia, and New Zealand, and Rest of Asia Pacific), South America (Brazil, Argentina, Chile, Colombia and Rest of South America), and Rest of the World (the Middle East, and Africa).

Key Takeaways

Choroidal Neovascularization Market: Market Share (%) by region, 2021

Choroidal Neovascularization (CNV) Market

For More Details on This Report - Request for Sample

Choroidal Neovascularization Market Segmentation Analysis- By Type

Choroidal Neovascularization Market based on type can be further segmented into Type-1 (occult), Type-2 (classic), and Type-3. Type-1 held a dominant market share in the year 2021 and is estimated to be the fastest-growing, with a CAGR of 7.9% over the forecast period of 2022-2027. According to the American Academy of Ophthalmology 2020, New vessels grow from the choriocapillaris into the subretinal pigment epithelial region, which is linked to damage to the outer retina. Type 1 neovascularization, also known as occult neovascularization, is the formation of new blood vessels behind the pigment epithelium. Damage to the pigment epithelium, the layer between the choroid and the retina, causes new capillaries to develop. The pigment epithelium might occasionally detach as a result of its development.

Signs and symptoms include; Painless loss of vision, Metamorphopsia, Paracentral or central scotoma, Apparent change in image size, Subretinal blood, Subretinal fluid Lipid exudation., Retinal pigment epithelial detachment, Subretinal fibrosis (disciform scar). Moreover, the morphological changes of eyes with subfoveal occult CNV in which the boundaries are poorly demarcated in a variable; the presence of subretinal blood or a component of classic CNV may influence the prognosis for further loss of vision. Hence, Type 1 neovascularization dominates the market.

Choroidal Neovascularization Market Segmentation Analysis- By Application

The choroidal Neovascularization Market based on the application can be further segmented into Age-related Macular Degeneration, Ocular Histoplasmosis, Pathologic Myopia, Eye trauma, and Angioid Streaks. segment Age-related Macular Degeneration held a dominant market share in the year 2021 and is estimated to be the fastest-growing, with a CAGR of 7.2% over the forecast period of 2022-2027 owing to the increased prevalence of Age-related Macular Degeneration. The macula is the pigmented region of the retina in the retina's very center. The fovea, located at the macula's center, is the most significant component of the eye. AMD (age-related macular degeneration) is an eye condition that causes central vision blurring. It occurs when the macula; the region of the eye that regulates crisp, straight-ahead vision is damaged as a result of aging.

According to NCBI 2020, age-related macular degeneration affects around 1 out of every 100 persons between the ages of 65 and 75, and 10 to 20 out of every 100 people beyond the age of 85. Macular degeneration is the most prevalent cause of serious vision loss in elderly persons in developed nations. Hence, age-related macular degeneration is dominating the market for Choroidal Neovascularization (CNV).

Choroidal Neovascularization Market Segmentation Analysis- By Geography

The Choroidal Neovascularization Market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America held a dominant market share of 39% in the year 2021 as compared to the other counterparts on account of the increasing aged population. According to NIH 2018, the number of people aged 65 and more in the Region Is anticipated to nearly double in the next three decades, from 48 million to 88 million by 2050, thereby, expanding regional industry.

However, Asia-Pacific is estimated to be the fastest-growing, over the forecast period of 2022-2027 on account of decreased awareness about eye disorders. According to ESCAP 2020, the number of elderly people in Asia and the Pacific is projected to more than quadruple by 2050, from 630 million in 2020 to almost 1.3 billion. In Asia and the Pacific, 13.6 percent of the population is 60 or older in 2020; by 2050, it will account for a quarter of the population, thus increasing geriatric population triggers age-related disorders which is expected to enhance the forecast growth in Asia-Pacific.

Choroidal Neovascularization Market Drivers

Growing Prevalence of Lifestyle Change Diseases Mainly Diabetes is Boosting the Market growth

Diabetes mellitus is a metabolic condition characterized by insulin secretion (type 1), insulin action (type 2), or both. Chronic hyperglycemia is one of its hallmarks, and it can cause malfunction and damage to a variety of organ systems, including the brain, kidneys, eyes, and peripheral nerves. The presence or absence of retinal neovascularization can be used to classify diabetic retinopathy. Intraretinal microvascular alterations that occur in the early phases of diabetic retinopathy are referred to as non-proliferative diabetic retinopathy (NPDR). Diabetic retinopathy is the most common cause of blindness in adults aged 20 to 74 in the United States. Diabetic retinopathy becomes increasingly common as diabetes mellitus progresses, and it affects the great majority of people who have had diabetes for 20 years or longer. PDR affects roughly 50% of individuals with type 1 diabetes, 5–10% of patients with noninsulin-dependent type 2 diabetes, and 30% of patients with insulin-dependent type 2 diabetes after 20 years of diabetes.

According to CDC, in 2021, Diabetic retinopathy (DR) is a common diabetic condition. It is the primary cause of blindness in adults in the United States. Progressive damage of the blood vessels of the retina, the light-sensitive tissue at the back of the eye that is required for good vision, characterizes it. Mild non-proliferative retinopathy (microaneurysms), moderate no proliferative retinopathy (blockage in some retinal vessels), severe no proliferative retinopathy (more vessels are blocked, depriving the retina of blood supply, resulting in the formation of new blood vessels), and proliferative retinopathy (growth of new blood vessels) are the four stages of DR (most advanced stage). Both eyes are generally affected by diabetic retinopathy. Thus, the Growing Prevalence of Lifestyle Change Diseases Mainly Diabetes is propelling the market growth.

The Rising Prevalence of Aging Population is Driving Market Growth

Age is a major risk factor for Age-related Macular Degeneration which is the main cause of Choroidal Neovascularization (CNV). According to the National Institute of Health 2018, From 68.6 years in 2015 to 76.2 years in 2050, global life expectancy at birth is expected to grow by over eight years. Between 2015 and 2050, the worldwide population of the "oldest old" persons aged 80 and above is predicted to be more than treble, rising from 126.5 million to 446.6 million. By 2050, the population of the elderly in several Asian and Latin American nations is expected to double. Noncommunicable illnesses are the leading cause of death among the world's elderly. The elderly in low-income nations, many of which are in Africa, incur a significant burden from both noncommunicable and communicable illnesses.

Choroidal Neovascularization Market Challenges

Lack of Awareness about Eye Disorders Poses Threat to Market Growth

According to WHO 2020, Near or far vision impairment affects at least 2.2 billion people globally. Moreover, in at least one billion of these cases, vision impairment might have been avoided if the patient had gotten an effective diagnosis and treatment. People are more likely to seek treatment for eye issues if they are aware of and understand prevalent eye disorders. This also aids in lowering the prevalence of vision impairment among a society's population. The primary causes of blindness in the world are cataracts, glaucoma, and diabetic retinopathy. Hence, a Lack of Awareness about Eye Disorders Poses a Threat to Market Growth.

Choroidal Neovascularization Industry Outlook

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Choroidal Neovascularization Market. Choroidal Neovascularization to 10 companies are-

  1. Pfizer Inc.
  2. F. Hoffmann-La Roche Ltd.
  3. Novartis AG
  4. Regeneron Pharmaceuticals Inc.
  5. Bayer AG
  6. QLT Inc.
  7. Sanwa Kagaku Kenkyusho Co. Ltd.
  8. Promedior Inc.
  9.  Bausch Health
  10. Gilead Sciences Inc

Recent Developments

  • In March 2022, Intas Pharmaceuticals launched a biosimilar of Lucentis®, (ranibizumab). Intas is the first firm in the world to develop and market a ranibizumab biosimilar. RAZUMABTM is a single-dose vial that is made under rigorous requirements for sterile use in the eye, decreasing the risk of contamination during usage. Ranibizumab is a therapeutic antibody fragment developed exclusively for the treatment of ocular degenerative diseases. It inhibits the synthesis of vascular endothelial cell growth factor A (VEGF-A), a protein that, when overexpressed in the retina, causes aberrant blood vessel development, leaks, and vision loss. With the mission to provide global healthcare at affordable costs, RAZUMABTM will be about 25 percent cheaper than the imported Lucentis® in the hand of the patient.
  • In January 2022, Roche got FDA approval for the monoclonal antibody named Vabysmo, formerly known as faricimab, which is a novel type of biological medication known as a bispecific antibody because it binds to two proteins instead of just one. In the instance of Vabysmo, Roche's medicine binds to two proteins: VEGF, which is targeted by Eylea and Lucentis, and Ang-2, which is not.
  • In October 2019, the FDA has authorized Novartis' Beovu® (brolucizumab) injectable, also known as RTH258, for the treatment of wet age-related macular degeneration (AMD). Beovu is the first FDA-approved anti-VEGF to provide both higher fluid resolution and the capacity to retain eligible wet AMD patients. Moreover, Novartis mentioned Beovu meets its goals in clinical practice for treating wet AMD: improving vision and drying retinal fluid.

Relevant Titles

Eye Infections Treatment Market - Forecast(2022 - 2027)

Report Code: HCR 0209

Eye Tracking Market - Forecast(2022 - 2027)

Report Code: ESR 0331

Vision Disorders Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2021 - 2026

Report Code: HCR 0608

For more Lifesciences and Healthcare Market reports, please click here

1. Choroidal Neovascularization (CNV) Market - Overview
    1.1 Definitions and Scope
2. Choroidal Neovascularization (CNV) Market - Executive Summary
3. Choroidal Neovascularization (CNV) Market - Comparative Analysis
    3.1 Company Benchmarking - Key Companies
    3.2 Global Financial Analysis - Key Companies
    3.3 Market Share Analysis - Key Companies
    3.4 Patent Analysis
    3.5 Pricing Analysis
4. Choroidal Neovascularization (CNV) Market - Startup Companies Scenario Premium
    4.1 Key Startup Company Analysis by
        4.1.1 Investment
        4.1.2 Revenue
        4.1.3 Venture Capital and Funding Scenario
5. Choroidal Neovascularization (CNV) Market – Industry Market Entry Scenario Premium Premium
    5.1 Regulatory Framework Overview
    5.2 New Business and Ease of Doing Business Index
    5.3 Case Studies of Successful Ventures
6. Choroidal Neovascularization (CNV) Market - Forces
    6.1 Market Drivers
    6.2 Market Constraints/Challenges
    6.3 Porters Five Force Model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes
7. Choroidal Neovascularization (CNV) Market – Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle
    8. Choroidal Neovascularization (CNV) Market – By Type
8.1 Type-1 (Occult)
    8.2 Type-2 (Classic)
    8.3 Type-3
9. Choroidal Neovascularization (CNV) Market – By Application
    9.1 Age-related Macular Degeneration
    9.2 Ocular Histoplasmosis
    9.3 Pathologic Myopia
    9.4 Eye trauma
    9.5 Angioid Streaks
10. Choroidal Neovascularization (CNV) Market – By Treatment
    10.1 Anti-VEGF drugs
    10.2 Thermal Laser Treatment (TLT)
    10.3 Others
11. Choroidal Neovascularization (CNV) Market - By Geography
    11.1 North America
        11.1.1 U.S.
        11.1.2 Canada
        11.1.3 Mexico
    11.2 Europe
        11.2.1 U.K.
        11.2.2 Germany
        11.2.3 France
        11.2.4 Italy
        11.2.5 Spain
        11.2.6 Russia
        11.2.7 Rest of Europe
    11.3 Asia-Pacific
        11.3.1 China
        11.3.2 India
        11.3.3 Japan
        11.3.4 South Korea
        11.3.5 Australia & New Zealand
        11.3.6 Rest of Asia-Pacific
    11.4 South America
        11.4.1 Brazil
        11.4.2 Argentina
        11.4.3 Chile
        11.4.4 Colombia
        11.4.5 Rest of South America
    11.5 Rest of the World
        11.5.1 Middle East
        11.5.2 Africa
12. Choroidal Neovascularization (CNV) Market - Entropy
13. Choroidal Neovascularization (CNV) Market – Industry/Segment Competition Landscape Premium 
    13.1 Market Share Analysis
        13.1.1 Global Market Share – Key Companies
        13.1.2 Market Share by Region – Key companies
        13.1.3 Market Share by Countries – Key Companies
    13.2 Competition Matrix
    13.3 Best Practices for Companies
14. Choroidal Neovascularization (CNV) Market – Key Company List by Country Premium Premium
15. Choroidal Neovascularization (CNV) Market - Company Analysis
    15.1 Company 1
    15.2 Company 2
    15.3 Company 3
    15.4 Company 4
    15.5 Company 5
    15.6 Company 6
    15.7 Company 7
    15.8 Company 8
    15.9 Company 9
15.10 Company 10
"*Financials for private companies would be provided on a best efforts basis*”.
List of Tables

Table 1: Choroidal Neovascularization (CNV) Market Overview 2021-2026
Table 2: Choroidal Neovascularization (CNV) Market Leader Analysis 2018-2019 (US$)
Table 3: Choroidal Neovascularization (CNV) Market Product Analysis 2018-2019 (US$)
Table 4: Choroidal Neovascularization (CNV) Market End User Analysis 2018-2019 (US$)
Table 5: Choroidal Neovascularization (CNV) Market Patent Analysis 2013-2018* (US$)
Table 6: Choroidal Neovascularization (CNV) Market Financial Analysis 2018-2019 (US$)
Table 7: Choroidal Neovascularization (CNV) Market Driver Analysis 2018-2019 (US$)
Table 8: Choroidal Neovascularization (CNV) Market Challenges Analysis 2018-2019 (US$)
Table 9: Choroidal Neovascularization (CNV) Market Constraint Analysis 2018-2019 (US$)
Table 10: Choroidal Neovascularization (CNV) Market Supplier Bargaining Power Analysis 2018-2019 (US$)
Table 11: Choroidal Neovascularization (CNV) Market Buyer Bargaining Power Analysis 2018-2019 (US$)
Table 12: Choroidal Neovascularization (CNV) Market Threat of Substitutes Analysis 2018-2019 (US$)
Table 13: Choroidal Neovascularization (CNV) Market Threat of New Entrants Analysis 2018-2019 (US$)
Table 14: Choroidal Neovascularization (CNV) Market Degree of Competition Analysis 2018-2019 (US$)
Table 15: Choroidal Neovascularization (CNV) Market Value Chain Analysis 2018-2019 (US$)
Table 16: Choroidal Neovascularization (CNV) Market Pricing Analysis 2021-2026 (US$)
Table 17: Choroidal Neovascularization (CNV) Market Opportunities Analysis 2021-2026 (US$)
Table 18: Choroidal Neovascularization (CNV) Market Product Life Cycle Analysis 2021-2026 (US$)
Table 19: Choroidal Neovascularization (CNV) Market Supplier Analysis 2018-2019 (US$)
Table 20: Choroidal Neovascularization (CNV) Market Distributor Analysis 2018-2019 (US$)
Table 21: Choroidal Neovascularization (CNV) Market Trend Analysis 2018-2019 (US$)
Table 22: Choroidal Neovascularization (CNV) Market Size 2018 (US$)
Table 23: Choroidal Neovascularization (CNV) Market Forecast Analysis 2021-2026 (US$)
Table 24: Choroidal Neovascularization (CNV) Market Sales Forecast Analysis 2021-2026 (Units)
Table 25: Choroidal Neovascularization (CNV) Market, Revenue & Volume,By Treatment Type, 2021-2026 ($)
Table 26: Choroidal Neovascularization (CNV) Market By Treatment Type, Revenue & Volume,By Angiogenesis Inhibitors Injection, 2021-2026 ($)
Table 27: Choroidal Neovascularization (CNV) Market By Treatment Type, Revenue & Volume,By Photodynamic Therapy, 2021-2026 ($)
Table 28: Choroidal Neovascularization (CNV) Market By Treatment Type, Revenue & Volume,By Laser photocoagulation, 2021-2026 ($)
Table 29: Choroidal Neovascularization (CNV) Market By Treatment Type, Revenue & Volume,By Low-dose Radiation Therapy, 2021-2026 ($)
Table 30: Choroidal Neovascularization (CNV) Market By Treatment Type, Revenue & Volume,By Surgery, 2021-2026 ($)
Table 31: Choroidal Neovascularization (CNV) Market, Revenue & Volume, By Type of Diagnosis, 2021-2026 ($)
Table 32: Choroidal Neovascularization (CNV) Market By Type of Diagnosis, Revenue & Volume,By Fluorescein angiography (FA), 2021-2026 ($)
Table 33: Choroidal Neovascularization (CNV) Market By Type of Diagnosis, Revenue & Volume,By Indocyanine green (ICG) angiography, 2021-2026 ($)
Table 34: Choroidal Neovascularization (CNV) Market By Type of Diagnosis, Revenue & Volume,By Spectral domain optical coherence tomography (OCT), 2021-2026 ($)
Table 35: North America Choroidal Neovascularization (CNV) Market, Revenue & Volume,By Treatment Type, 2021-2026 ($)
Table 36: North America Choroidal Neovascularization (CNV) Market, Revenue & Volume, By Type of Diagnosis, 2021-2026 ($)
Table 37: South america Choroidal Neovascularization (CNV) Market, Revenue & Volume,By Treatment Type, 2021-2026 ($)
Table 38: South america Choroidal Neovascularization (CNV) Market, Revenue & Volume, By Type of Diagnosis, 2021-2026 ($)
Table 39: Europe Choroidal Neovascularization (CNV) Market, Revenue & Volume,By Treatment Type, 2021-2026 ($)
Table 40: Europe Choroidal Neovascularization (CNV) Market, Revenue & Volume, By Type of Diagnosis, 2021-2026 ($)
Table 41: APAC Choroidal Neovascularization (CNV) Market, Revenue & Volume,By Treatment Type, 2021-2026 ($)
Table 42: APAC Choroidal Neovascularization (CNV) Market, Revenue & Volume, By Type of Diagnosis, 2021-2026 ($)
Table 43: Middle East & Africa Choroidal Neovascularization (CNV) Market, Revenue & Volume,By Treatment Type, 2021-2026 ($)
Table 44: Middle East & Africa Choroidal Neovascularization (CNV) Market, Revenue & Volume, By Type of Diagnosis, 2021-2026 ($)
Table 45: Russia Choroidal Neovascularization (CNV) Market, Revenue & Volume,By Treatment Type, 2021-2026 ($)
Table 46: Russia Choroidal Neovascularization (CNV) Market, Revenue & Volume, By Type of Diagnosis, 2021-2026 ($)
Table 47: Israel Choroidal Neovascularization (CNV) Market, Revenue & Volume,By Treatment Type, 2021-2026 ($)
Table 48: Israel Choroidal Neovascularization (CNV) Market, Revenue & Volume, By Type of Diagnosis, 2021-2026 ($)
Table 49: Top Companies 2018 (US$)Choroidal Neovascularization (CNV) Market, Revenue & Volume
Table 50: Product Launch 2018-2019Choroidal Neovascularization (CNV) Market, Revenue & Volume
Table 51: Mergers & Acquistions 2018-2019Choroidal Neovascularization (CNV) Market, Revenue & Volume


List of Figures
Figure 1: Overview of Choroidal Neovascularization (CNV) Market 2021-2026
Figure 2: Market Share Analysis for Choroidal Neovascularization (CNV) Market 2018 (US$)
Figure 3: Product Comparison in Choroidal Neovascularization (CNV) Market 2018-2019 (US$)
Figure 4: End User Profile for Choroidal Neovascularization (CNV) Market 2018-2019 (US$)
Figure 5: Patent Application and Grant in Choroidal Neovascularization (CNV) Market 2013-2018* (US$)
Figure 6: Top 5 Companies Financial Analysis in Choroidal Neovascularization (CNV) Market 2018-2019 (US$)
Figure 7: Market Entry Strategy in Choroidal Neovascularization (CNV) Market 2018-2019
Figure 8: Ecosystem Analysis in Choroidal Neovascularization (CNV) Market 2018
Figure 9: Average Selling Price in Choroidal Neovascularization (CNV) Market 2021-2026
Figure 10: Top Opportunites in Choroidal Neovascularization (CNV) Market 2018-2019
Figure 11: Market Life Cycle Analysis in Choroidal Neovascularization (CNV) Market
Figure 12: GlobalBy Treatment Type Choroidal Neovascularization (CNV) Market Revenue, 2021-2026 ($)
Figure 13: Global By Type of Diagnosis Choroidal Neovascularization (CNV) Market Revenue, 2021-2026 ($)
Figure 14: Global Choroidal Neovascularization (CNV) Market - By Geography
Figure 15: Global Choroidal Neovascularization (CNV) Market Value & Volume, By Geography, 2021-2026 ($) 
Figure 16: Global Choroidal Neovascularization (CNV) Market CAGR, By Geography, 2021-2026 (%)
Figure 17: North America Choroidal Neovascularization (CNV) Market Value & Volume, 2021-2026 ($)
Figure 18: US Choroidal Neovascularization (CNV) Market Value & Volume, 2021-2026 ($)
Figure 19: US GDP and Population, 2018-2019 ($)
Figure 20: US GDP – Composition of 2018, By Sector of Origin
Figure 21: US Export and Import Value & Volume, 2018-2019 ($)
Figure 22: Canada Choroidal Neovascularization (CNV) Market Value & Volume, 2021-2026 ($)
Figure 23: Canada GDP and Population, 2018-2019 ($)
Figure 24: Canada GDP – Composition of 2018, By Sector of Origin
Figure 25: Canada Export and Import Value & Volume, 2018-2019 ($)
Figure 26: Mexico Choroidal Neovascularization (CNV) Market Value & Volume, 2021-2026 ($)
Figure 27: Mexico GDP and Population, 2018-2019 ($)
Figure 28: Mexico GDP – Composition of 2018, By Sector of Origin
Figure 29: Mexico Export and Import Value & Volume, 2018-2019 ($)
Figure 30: South America Choroidal Neovascularization (CNV) Market Value & Volume, 2021-2026 ($)
Figure 31: Brazil Choroidal Neovascularization (CNV) Market Value & Volume, 2021-2026 ($)
Figure 32: Brazil GDP and Population, 2018-2019 ($)
Figure 33: Brazil GDP – Composition of 2018, By Sector of Origin
Figure 34: Brazil Export and Import Value & Volume, 2018-2019 ($)
Figure 35: Venezuela Choroidal Neovascularization (CNV) Market Value & Volume, 2021-2026 ($)
Figure 36: Venezuela GDP and Population, 2018-2019 ($)
Figure 37: Venezuela GDP – Composition of 2018, By Sector of Origin
Figure 38: Venezuela Export and Import Value & Volume, 2018-2019 ($)
Figure 39: Argentina Choroidal Neovascularization (CNV) Market Value & Volume, 2021-2026 ($)
Figure 40: Argentina GDP and Population, 2018-2019 ($)
Figure 41: Argentina GDP – Composition of 2018, By Sector of Origin
Figure 42: Argentina Export and Import Value & Volume, 2018-2019 ($)
Figure 43: Ecuador Choroidal Neovascularization (CNV) Market Value & Volume, 2021-2026 ($)
Figure 44: Ecuador GDP and Population, 2018-2019 ($)
Figure 45: Ecuador GDP – Composition of 2018, By Sector of Origin
Figure 46: Ecuador Export and Import Value & Volume, 2018-2019 ($)
Figure 47: Peru Choroidal Neovascularization (CNV) Market Value & Volume, 2021-2026 ($)
Figure 48: Peru GDP and Population, 2018-2019 ($)
Figure 49: Peru GDP – Composition of 2018, By Sector of Origin
Figure 50: Peru Export and Import Value & Volume, 2018-2019 ($)
Figure 51: Colombia Choroidal Neovascularization (CNV) Market Value & Volume, 2021-2026 ($)
Figure 52: Colombia GDP and Population, 2018-2019 ($)
Figure 53: Colombia GDP – Composition of 2018, By Sector of Origin
Figure 54: Colombia Export and Import Value & Volume, 2018-2019 ($)
Figure 55: Costa Rica Choroidal Neovascularization (CNV) Market Value & Volume, 2021-2026 ($)
Figure 56: Costa Rica GDP and Population, 2018-2019 ($)
Figure 57: Costa Rica GDP – Composition of 2018, By Sector of Origin
Figure 58: Costa Rica Export and Import Value & Volume, 2018-2019 ($)
Figure 59: Europe Choroidal Neovascularization (CNV) Market Value & Volume, 2021-2026 ($)
Figure 60: U.K Choroidal Neovascularization (CNV) Market Value & Volume, 2021-2026 ($)
Figure 61: U.K GDP and Population, 2018-2019 ($)
Figure 62: U.K GDP – Composition of 2018, By Sector of Origin
Figure 63: U.K Export and Import Value & Volume, 2018-2019 ($)
Figure 64: Germany Choroidal Neovascularization (CNV) Market Value & Volume, 2021-2026 ($)
Figure 65: Germany GDP and Population, 2018-2019 ($)
Figure 66: Germany GDP – Composition of 2018, By Sector of Origin
Figure 67: Germany Export and Import Value & Volume, 2018-2019 ($)
Figure 68: Italy Choroidal Neovascularization (CNV) Market Value & Volume, 2021-2026 ($)
Figure 69: Italy GDP and Population, 2018-2019 ($)
Figure 70: Italy GDP – Composition of 2018, By Sector of Origin
Figure 71: Italy Export and Import Value & Volume, 2018-2019 ($)
Figure 72: France Choroidal Neovascularization (CNV) Market Value & Volume, 2021-2026 ($)
Figure 73: France GDP and Population, 2018-2019 ($)
Figure 74: France GDP – Composition of 2018, By Sector of Origin
Figure 75: France Export and Import Value & Volume, 2018-2019 ($)
Figure 76: Netherlands Choroidal Neovascularization (CNV) Market Value & Volume, 2021-2026 ($)
Figure 77: Netherlands GDP and Population, 2018-2019 ($)
Figure 78: Netherlands GDP – Composition of 2018, By Sector of Origin
Figure 79: Netherlands Export and Import Value & Volume, 2018-2019 ($)
Figure 80: Belgium Choroidal Neovascularization (CNV) Market Value & Volume, 2021-2026 ($)
Figure 81: Belgium GDP and Population, 2018-2019 ($)
Figure 82: Belgium GDP – Composition of 2018, By Sector of Origin
Figure 83: Belgium Export and Import Value & Volume, 2018-2019 ($)
Figure 84: Spain Choroidal Neovascularization (CNV) Market Value & Volume, 2021-2026 ($)
Figure 85: Spain GDP and Population, 2018-2019 ($)
Figure 86: Spain GDP – Composition of 2018, By Sector of Origin
Figure 87: Spain Export and Import Value & Volume, 2018-2019 ($)
Figure 88: Denmark Choroidal Neovascularization (CNV) Market Value & Volume, 2021-2026 ($)
Figure 89: Denmark GDP and Population, 2018-2019 ($)
Figure 90: Denmark GDP – Composition of 2018, By Sector of Origin
Figure 91: Denmark Export and Import Value & Volume, 2018-2019 ($)
Figure 92: APAC Choroidal Neovascularization (CNV) Market Value & Volume, 2021-2026 ($)
Figure 93: China Choroidal Neovascularization (CNV) Market Value & Volume, 2021-2026
Figure 94: China GDP and Population, 2018-2019 ($)
Figure 95: China GDP – Composition of 2018, By Sector of Origin
Figure 96: China Export and Import Value & Volume, 2018-2019 ($)Choroidal Neovascularization (CNV) Market China Export and Import Value & Volume, 2018-2019 ($)
Figure 97: Australia Choroidal Neovascularization (CNV) Market Value & Volume, 2021-2026 ($)
Figure 98: Australia GDP and Population, 2018-2019 ($)
Figure 99: Australia GDP – Composition of 2018, By Sector of Origin
Figure 100: Australia Export and Import Value & Volume, 2018-2019 ($)
Figure 101: South Korea Choroidal Neovascularization (CNV) Market Value & Volume, 2021-2026 ($)
Figure 102: South Korea GDP and Population, 2018-2019 ($)
Figure 103: South Korea GDP – Composition of 2018, By Sector of Origin
Figure 104: South Korea Export and Import Value & Volume, 2018-2019 ($)
Figure 105: India Choroidal Neovascularization (CNV) Market Value & Volume, 2021-2026 ($)
Figure 106: India GDP and Population, 2018-2019 ($)
Figure 107: India GDP – Composition of 2018, By Sector of Origin
Figure 108: India Export and Import Value & Volume, 2018-2019 ($)
Figure 109: Taiwan Choroidal Neovascularization (CNV) Market Value & Volume, 2021-2026 ($)
Figure 110: Taiwan GDP and Population, 2018-2019 ($)
Figure 111: Taiwan GDP – Composition of 2018, By Sector of Origin
Figure 112: Taiwan Export and Import Value & Volume, 2018-2019 ($)
Figure 113: Malaysia Choroidal Neovascularization (CNV) Market Value & Volume, 2021-2026 ($)
Figure 114: Malaysia GDP and Population, 2018-2019 ($)
Figure 115: Malaysia GDP – Composition of 2018, By Sector of Origin
Figure 116: Malaysia Export and Import Value & Volume, 2018-2019 ($)
Figure 117: Hong Kong Choroidal Neovascularization (CNV) Market Value & Volume, 2021-2026 ($)
Figure 118: Hong Kong GDP and Population, 2018-2019 ($)
Figure 119: Hong Kong GDP – Composition of 2018, By Sector of Origin
Figure 120: Hong Kong Export and Import Value & Volume, 2018-2019 ($)
Figure 121: Middle East & Africa Choroidal Neovascularization (CNV) Market Middle East & Africa 3D Printing Market Value & Volume, 2021-2026 ($)
Figure 122: Russia Choroidal Neovascularization (CNV) Market Value & Volume, 2021-2026 ($)
Figure 123: Russia GDP and Population, 2018-2019 ($)
Figure 124: Russia GDP – Composition of 2018, By Sector of Origin
Figure 125: Russia Export and Import Value & Volume, 2018-2019 ($)
Figure 126: Israel Choroidal Neovascularization (CNV) Market Value & Volume, 2021-2026 ($)
Figure 127: Israel GDP and Population, 2018-2019 ($)
Figure 128: Israel GDP – Composition of 2018, By Sector of Origin
Figure 129: Israel Export and Import Value & Volume, 2018-2019 ($)
Figure 130: Entropy Share, By Strategies, 2018-2019* (%)Choroidal Neovascularization (CNV) Market 
Figure 131: Developments, 2018-2019*Choroidal Neovascularization (CNV) Market 
Figure 132: Company 1 Choroidal Neovascularization (CNV) Market Net Revenue, By Years, 2018-2019* ($)
Figure 133: Company 1 Choroidal Neovascularization (CNV) Market Net Revenue Share, By Business segments, 2018 (%)
Figure 134: Company 1 Choroidal Neovascularization (CNV) Market Net Sales Share, By Geography, 2018 (%)
Figure 135: Company 2 Choroidal Neovascularization (CNV) Market Net Revenue, By Years, 2018-2019* ($)
Figure 136: Company 2 Choroidal Neovascularization (CNV) Market Net Revenue Share, By Business segments, 2018 (%)
Figure 137: Company 2 Choroidal Neovascularization (CNV) Market Net Sales Share, By Geography, 2018 (%)
Figure 138: Company 3Choroidal Neovascularization (CNV) Market Net Revenue, By Years, 2018-2019* ($)
Figure 139: Company 3Choroidal Neovascularization (CNV) Market Net Revenue Share, By Business segments, 2018 (%)
Figure 140: Company 3Choroidal Neovascularization (CNV) Market Net Sales Share, By Geography, 2018 (%)
Figure 141: Company 4 Choroidal Neovascularization (CNV) Market Net Revenue, By Years, 2018-2019* ($)
Figure 142: Company 4 Choroidal Neovascularization (CNV) Market Net Revenue Share, By Business segments, 2018 (%)
Figure 143: Company 4 Choroidal Neovascularization (CNV) Market Net Sales Share, By Geography, 2018 (%)
Figure 144: Company 5 Choroidal Neovascularization (CNV) Market Net Revenue, By Years, 2018-2019* ($)
Figure 145: Company 5 Choroidal Neovascularization (CNV) Market Net Revenue Share, By Business segments, 2018 (%)
Figure 146: Company 5 Choroidal Neovascularization (CNV) Market Net Sales Share, By Geography, 2018 (%)
Figure 147: Company 6 Choroidal Neovascularization (CNV) Market Net Revenue, By Years, 2018-2019* ($)
Figure 148: Company 6 Choroidal Neovascularization (CNV) Market Net Revenue Share, By Business segments, 2018 (%)
Figure 149: Company 6 Choroidal Neovascularization (CNV) Market Net Sales Share, By Geography, 2018 (%)
Figure 150: Company 7 Choroidal Neovascularization (CNV) Market Net Revenue, By Years, 2018-2019* ($)
Figure 151: Company 7 Choroidal Neovascularization (CNV) Market Net Revenue Share, By Business segments, 2018 (%)
Figure 152: Company 7 Choroidal Neovascularization (CNV) Market Net Sales Share, By Geography, 2018 (%)
Figure 153: Company 8 Choroidal Neovascularization (CNV) Market Net Revenue, By Years, 2018-2019* ($)
Figure 154: Company 8 Choroidal Neovascularization (CNV) Market Net Revenue Share, By Business segments, 2018 (%)
Figure 155: Company 8 Choroidal Neovascularization (CNV) Market Net Sales Share, By Geography, 2018 (%)
Figure 156: Company 9 Choroidal Neovascularization (CNV) Market Net Revenue, By Years, 2018-2019* ($)
Figure 157: Company 9 Choroidal Neovascularization (CNV) Market Net Revenue Share, By Business segments, 2018 (%)
Figure 158: Company 9 Choroidal Neovascularization (CNV) Market Net Sales Share, By Geography, 2018 (%)
Figure 159: Company 10 Choroidal Neovascularization (CNV) Market Net Revenue, By Years, 2018-2019* ($)
Figure 160: Company 10 Choroidal Neovascularization (CNV) Market Net Revenue Share, By Business segments, 2018 (%)
Figure 161: Company 10 Choroidal Neovascularization (CNV) Market Net Sales Share, By Geography, 2018 (%)
Figure 162: Company 11 Choroidal Neovascularization (CNV) Market Net Revenue, By Years, 2018-2019* ($)
Figure 163: Company 11 Choroidal Neovascularization (CNV) Market Net Revenue Share, By Business segments, 2018 (%)
Figure 164: Company 11 Choroidal Neovascularization (CNV) Market Net Sales Share, By Geography, 2018 (%)
Figure 165: Company 12 Choroidal Neovascularization (CNV) Market Net Revenue, By Years, 2018-2019* ($)
Figure 166: Company 12 Choroidal Neovascularization (CNV) Market Net Revenue Share, By Business segments, 2018 (%)
Figure 167: Company 12 Choroidal Neovascularization (CNV) Market Net Sales Share, By Geography, 2018 (%)
Figure 168: Company 13Choroidal Neovascularization (CNV) Market Net Revenue, By Years, 2018-2019* ($)
Figure 169: Company 13Choroidal Neovascularization (CNV) Market Net Revenue Share, By Business segments, 2018 (%)
Figure 170: Company 13Choroidal Neovascularization (CNV) Market Net Sales Share, By Geography, 2018 (%)
Figure 171: Company 14 Choroidal Neovascularization (CNV) Market Net Revenue, By Years, 2018-2019* ($)
Figure 172: Company 14 Choroidal Neovascularization (CNV) Market Net Revenue Share, By Business segments, 2018 (%)
Figure 173: Company 14 Choroidal Neovascularization (CNV) Market Net Sales Share, By Geography, 2018 (%)
Figure 174: Company 15 Choroidal Neovascularization (CNV) Market Net Revenue, By Years, 2018-2019* ($)
Figure 175: Company 15 Choroidal Neovascularization (CNV) Market Net Revenue Share, By Business segments, 2018 (%)
Figure 176: Company 15 Choroidal Neovascularization (CNV) Market Net Sales Share, By Geography, 2018 (%)